Fractal-based Gait Training in Older Adults

Fractal-based Gait Training in Older Adults: Implications to Motor Control and Neuroplasticity

The purpose of the study is to investigate the influence of walking with external visual cues on brain adaptations.

Study Overview

Status

Enrolling by invitation

Conditions

Study Type

Interventional

Enrollment (Estimated)

66

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Monte de Caparica
      • Almada, Monte de Caparica, Portugal, 2829-699
        • Egas Moniz School of Health and Science

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Exclusion Criteria:

  • Neurologic conditions;
  • Lower limb disabilities or disease;
  • Not able to provide informed consent;
  • Unable to walk unassisted for 10-minutes continuously;
  • Score below 24 in the Mini-Mental State Examination (MMSE);
  • Have a history of falls in the prior six months;
  • Have an implanted device (e.g., pacemakers);
  • Medication advised against the application of Transcranial Magnetic Stimulation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Control
Walking in a treadmill
Experimental: Fractal
Walking in a treadmill while synchronizing their steps with fractal external visual cues
Experimental: Isochronous
Walking in a treadmill while synchronizing their steps with isochronous external visual cues

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fractal scaling exponent (α) changes from baseline (PRE to POS, PRE to FUP, POS to FUP) both within and between Fractal, Isochronous and Control groups.
Time Frame: PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
The fractal scaling exponent quantifies the complexity of a physiological signal and detects the presence of statistical persistence in a given time series. This parameter is calculated using Detrended Fluctuation Analysis (DFA) from each time series (stride time and stride length).
PRE (baseline), POS (4 weeks after), FUP (8 weeks after)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Corticospinal excitability (CSE) changes from baseline (PRE to POS, PRE to FUP, POS to FUP) both within and between Fractal, Isochronous and Control groups.
Time Frame: PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
CSE is a parameter extracted through the application of Transcranial Magnetic Stimulation (TMS). This parameter provides information regarding the level of excitability of the corticospinal tract.
PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
Short-Interval Intracortical Inhibition (SICI) changes from baseline (PRE to POS, PRE to FUP, POS to FUP) both within and between Fractal, Isochronous and Control groups.
Time Frame: PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
SICI is a parameter extracted through the application of Transcranial Magnetic Stimulation (TMS). This parameter provides information regarding the level of inhibition of the motor cortex.
PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
Intracortical Facilitation (ICF) changes from baseline (PRE to POS, PRE to FUP, POS to FUP) both within and between Fractal, Isochronous and Control groups.
Time Frame: PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
ICF is a parameter extracted through the application of Transcranial Magnetic Stimulation (TMS). This parameter provides information regarding the level of facilitation of the motor cortex.
PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
Ankle, Knee and Hip joints range of motion's changes from baseline (PRE to POS, PRE to FUP, POS to FUP) both within and between Fractal, Isochronous and Control groups during a gait cycle
Time Frame: PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
Joint range of motion is measured through a motion capture system and quantifies the excursion of the joint during the gait task in degrees (º).
PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
Ankle, Knee and Hip joints maximum value changes from baseline (PRE to POS, PRE to FUP, POS to FUP) both within and between Fractal, Isochronous and Control groups during a gait cycle
Time Frame: PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
Joint maximum value is measured through a motion capture system and quantifies the maximum joint flexion during the gait task in degrees (º). This measure will be used to calculate joint range of motion (outcome 2).
PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
Ankle, Knee and Hip joints minimum value changes from baseline (PRE to POS, PRE to FUP, POS to FUP) both within and between Fractal, Isochronous and Control groups during a gait cycle
Time Frame: PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
Joint minimum value is measured through a motion capture system and quantifies the minimum joint flexion during the gait task in degrees (º). This measure will be used to calculate joint range of motion (outcome 2).
PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
Ankle, Knee and Hip joints angles during initial contact changes from baseline (PRE to POS, PRE to FUP, POS to FUP) both within and between Fractal, Isochronous and Control groups during a gait cycle
Time Frame: PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
Joint angle during initial contact is measured through a motion capture system and quantifies the angle of the respective joint at the moment the heel touches the ground during a gait cycle (heel strike) in degrees (º).
PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
Ankle, Knee and Hip joints angles during peak ground reaction force changes from baseline (PRE to POS, PRE to FUP, POS to FUP) both within and between Fractal, Isochronous and Control groups during a gait cycle
Time Frame: PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
Coefficient of variation (CV) changes from baseline (PRE to POS, PRE to FUP, POS to FUP) both within and between Fractal, Isochronous and Control groups.
Time Frame: PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
CV is a common linear measure that translates the amount of variability within the signal and is calculated through the standard deviation normalised to the mean from each time series (stride time and stride length).
PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
Electromyography co-contraction changes from baseline (PRE to POS, PRE to FUP, POS to FUP) both within and between Fractal, Isochronous and Control groups.
Time Frame: PRE (baseline), POS (4 weeks after), FUP (8 weeks after)
Co-contraction is the simultaneous activation of the agonist and antagonist muscles during a task. This parameter It is an important mechanism of the central nervous system to regulate joint stability and provide movement accuracy.
PRE (baseline), POS (4 weeks after), FUP (8 weeks after)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 25, 2024

Primary Completion (Estimated)

July 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

June 19, 2024

First Submitted That Met QC Criteria

July 11, 2024

First Posted (Actual)

July 18, 2024

Study Record Updates

Last Update Posted (Actual)

September 22, 2025

Last Update Submitted That Met QC Criteria

September 16, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Aging

Clinical Trials on Fractal

Subscribe